Entera Bio Ltd. P/B ratio

P/B ratio of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/B ratio growth rates and interactive chart. Measures the relationship between price and book value per share. Book value is the equity or owner's capital that is invested in a business. If a stock has a price of $10 and a book value per share of $10, the ratio is 1. Stock selling below a P/B of 1 can be a bargain, as the market price has declined below the net asset value of the business. It is more applicable to financial companies like banks and insurers, as their assets and liabilities are valued at market and the book value thus more accuraterly represents reality.


Highlights and Quick Summary

Current P/B ratio of Entera Bio Ltd. is 2.18 (as of December 30, 2019)
  • P/B ratio for the quarter ending June 29, 2020 was 4.64 (a 25.13% increase compared to previous quarter)
  • Year-over-year quarterly P/B ratio decreased by -37.51%
  • Annual P/B ratio for 2019 was 2.18 (a -53.9% decrease from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/B ratio of Entera Bio Ltd.

Most recent P/B ratioof ENTX including historical data for past 10 years.

Interactive Chart of P/B ratio of Entera Bio Ltd.

Entera Bio Ltd. P/B ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 4.64 3.71
2019 2.18 7.43 6.15 2.18
2018 4.73 4.73

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.